High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer.
作者信息
Suzman Daniel L, Antonarakis Emmanuel S
机构信息
Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore MD.
Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore MD.
出版信息
Clin Genitourin Cancer. 2014 Apr;12(2):e51-3. doi: 10.1016/j.clgc.2013.11.015. Epub 2013 Nov 14.
Abstract
摘要
相似文献
1
High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer.
Clin Genitourin Cancer. 2014 Apr;12(2):e51-3. doi: 10.1016/j.clgc.2013.11.015. Epub 2013 Nov 14.
2
Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.
Clin Genitourin Cancer. 2019 Feb;17(1):e92-e96. doi: 10.1016/j.clgc.2018.09.013. Epub 2018 Sep 24.
3
Biochemical recurrence of prostate cancer.
Curr Probl Cancer. 2003 Sep-Oct;27(5):243-72. doi: 10.1016/s0147-0272(03)00032-1.
4
[AUO study in hormone-refractory prostate cancer. Phase III study on treatment of hormone-refractory prostate cancer (HRPC) with docetaxel: continuous treatment vs. intermittent repetition of treatment after renewed progression--PRINCE].
Urologe A. 2006 Jul;45(7):872. doi: 10.1007/s00120-006-1117-4.
5
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
Prostate. 2012 Apr;72(5):487-98. doi: 10.1002/pros.21449. Epub 2011 Jul 11.
6
Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.
Med Oncol. 2016 Aug;33(8):89. doi: 10.1007/s12032-016-0806-0. Epub 2016 Jul 11.
7
Re: Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
J Urol. 2013 Sep;190(3):880. doi: 10.1016/j.juro.2013.05.105. Epub 2013 Jun 7.
8
Hormone therapy can wait in PSA-only relapse.
J Natl Cancer Inst. 2014 Aug 13;106(8). doi: 10.1093/jnci/dju278. Print 2014 Aug.
9
Pictorial review. Diagnosis of recurrent prostate cancer and its mimics at multiparametric prostate MRI.
Br J Radiol. 2015 Oct;88(1054):20150362. doi: 10.1259/bjr.20150362. Epub 2015 Aug 13.
10
Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
Int J Urol. 2019 Mar;26(3):426-428. doi: 10.1111/iju.13870. Epub 2018 Nov 21.
引用本文的文献
1
Itraconazole inhibits the Wnt/β-catenin signaling pathway to induce tumor-associated macrophages polarization to enhance the efficacy of immunotherapy in endometrial cancer.
Front Oncol. 2025 Jul 8;15:1590095. doi: 10.3389/fonc.2025.1590095. eCollection 2025.
2
Potential Benefits of Adding Alendronate, Celecoxib, Itraconazole, Ramelteon, and Simvastatin to Endometrial Cancer Treatment: The EC5 Regimen.
Curr Issues Mol Biol. 2025 Feb 26;47(3):153. doi: 10.3390/cimb47030153.
3
Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole.
Onco Targets Ther. 2019 Aug 23;12:6875-6886. doi: 10.2147/OTT.S223119. eCollection 2019.
4
Itraconazole inhibits the proliferation of gastric cancer cells and improves patient survival.
Oncol Lett. 2018 Sep;16(3):3651-3657. doi: 10.3892/ol.2018.9072. Epub 2018 Jul 4.
5
Repurposing itraconazole for the treatment of cancer.
Oncol Lett. 2017 Sep;14(3):2587-2597. doi: 10.3892/ol.2017.6569. Epub 2017 Jul 10.
6
Clinical Implications of Hedgehog Pathway Signaling in Prostate Cancer.
Cancers (Basel). 2015 Sep 29;7(4):1983-93. doi: 10.3390/cancers7040871.
7
Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.
Ecancermedicalscience. 2015 Apr 15;9:521. doi: 10.3332/ecancer.2015.521. eCollection 2015.
8
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Oncotarget. 2014 Sep 30;5(18):8052-82. doi: 10.18632/oncotarget.2408.
本文引用的文献
1
Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.
Oncologist. 2013;18(2):163-73. doi: 10.1634/theoncologist.2012-314. Epub 2013 Jan 22.
2
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.
Cancer Cell. 2010 Apr 13;17(4):388-99. doi: 10.1016/j.ccr.2010.02.027.
3
Hedgehog signalling in androgen independent prostate cancer.
Eur Urol. 2008 Dec;54(6):1333-43. doi: 10.1016/j.eururo.2008.01.070. Epub 2008 Feb 4.
4
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
J Clin Oncol. 2006 Sep 20;24(27):4448-56. doi: 10.1200/JCO.2006.06.2497.
5
Activation of the hedgehog pathway in advanced prostate cancer.
Mol Cancer. 2004 Oct 13;3:29. doi: 10.1186/1476-4598-3-29.
6
Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling.
Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6. doi: 10.1073/pnas.0404956101. Epub 2004 Aug 16.
7
Hedgehog signaling in animal development: paradigms and principles.
Genes Dev. 2001 Dec 1;15(23):3059-87. doi: 10.1101/gad.938601.
8
Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.
J Urol. 2000 Jun;163(6):1743-6.
9
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
J Urol. 1997 Apr;157(4):1204-7.
Zotero 插件